1. Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL
- Author
-
Aileen Arevalo, Neal Patel, Peter Muraki, Shinji Ohtake, Gennady Bratslavsky, Chandra Clark, Joshua Mann, Othon Iliopoulos, Eric Jonasch, Ramaprasad Srinivasan, and Brian Shuch
- Subjects
VHL ,kidney cancer ,systemic therapy ,Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Belzutifan was recently approved for the management of Von Hippel–Lindau disease (VHL). Given the morbidity of recurrent treatment, systemic therapy to reduce or eliminate the need for surgery has been long-awaited. Herein, we sought to gain insight about future utilization by surveying VHL experts in the United States. A survey developed by members of the VHL Alliance (VHLA) Clinical Advisory Council was distributed to kidney cancer providers at VHLA and National Comprehensive Cancer Network (NCCN) centers. Surveys were administered on a secure web-based platform. A total of 60 respondents from 29 institutions participated. Urologists (50%) and medical oncologists (43%) represented the majority of participants. The majority (98%) of respondents anticipated that belzutifan’s approval would signifi-cantly change the current treatment landscape. Most reported that therapy should be continuous (76%). There was a difference in willingness to prescribe belzutifan by specialty (38% of urologists vs 91% of medical oncologists (P = 0.02). In individuals with renal tumors
- Published
- 2022
- Full Text
- View/download PDF